Unknown

Dataset Information

0

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.


ABSTRACT: We have previously demonstrated the pharmacokinetic-pharmacodynamic (PK-PD) index best associated with the efficacy of tazobactam when used in combination with ceftolozane to be the percentage of the dosing interval during which tazobactam concentrations remained above a threshold value (%time>threshold). Using anin vitroinfection model and the same isogenic CTX-M-15-producingEscherichia colitriplet set genetically engineered to transcribe different levels ofblaCTX-M-15, herein we describe dose fractionation studies designed to evaluate the PK-PD index associated with tazobactam efficacy, when given in combination with piperacillin, and the impact of the presence of a different ?-lactam agent, or differentblaCTX-M-15transcription levels, on the magnitude of the tazobactam PK-PD index necessary for efficacy. The recombinant strains demonstrated piperacillin MIC values of 128, >256, and >256 ?g/ml for the low-, moderate-, and high-level CTX-M-15-producingE. colistrains, respectively. The MIC value for piperacillin in the presence of 4 ?g/ml of tazobactam was 2 ?g/ml for all three strains. The PK-PD index associated with tazobactam efficacy was confirmed to be %time>threshold, regardless of ?-lactamase transcription (r(2)= 0.839). The tazobactam concentration thresholds, however, changed with the CTX-M-15 transcription level and were 0.25, 0.5, and 2 ?g/ml for the low-, moderate-, and high-level CTX-M-15-producing strains, respectively (r(2)= 0.921, 0.773, and 0.875, respectively). The %time>threshold values for tazobactam necessary for net bacterial stasis and a 1- and 2-log10-unit CFU/ml decrease from baseline at 24 h were 44.9, 62.9, and 84.9%, respectively. In addition to verifying our previous study results, these results also demonstrated that the magnitude of bacterial-cell killing associated with a ?-lactam-?-lactamase inhibitor combination is dependent on the amount of ?-lactamase produced. These data provide important information for the development of ?-lactam-?-lactamase inhibitor combination agents.

SUBMITTER: Nicasio AM 

PROVIDER: S-EPMC4808219 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.

Nicasio Anthony M AM   VanScoy Brian D BD   Mendes Rodrigo E RE   Castanheira Mariana M   Bulik Catharine C CC   Okusanya Olanrewaju O OO   Bhavnani Sujata M SM   Forrest Alan A   Jones Ronald N RN   Friedrich Lawrence V LV   Steenbergen Judith N JN   Ambrose Paul G PG  

Antimicrobial agents and chemotherapy 20160325 4


We have previously demonstrated the pharmacokinetic-pharmacodynamic (PK-PD) index best associated with the efficacy of tazobactam when used in combination with ceftolozane to be the percentage of the dosing interval during which tazobactam concentrations remained above a threshold value (%time>threshold). Using anin vitroinfection model and the same isogenic CTX-M-15-producingEscherichia colitriplet set genetically engineered to transcribe different levels ofblaCTX-M-15, herein we describe dose  ...[more]

Similar Datasets

| S-EPMC8093170 | biostudies-literature
| S-EPMC3302674 | biostudies-literature
2014-11-30 | GSE62794 | GEO
| S-EPMC6811421 | biostudies-literature
| S-EPMC6496078 | biostudies-literature